Last reviewed · How we verify

Gastrografin®: G

University of Bologna · FDA-approved active Small molecule

Gastrografin is a water-soluble iodinated contrast medium that opacifies the gastrointestinal tract for radiographic imaging.

Gastrografin is a water-soluble iodinated contrast medium that opacifies the gastrointestinal tract for radiographic imaging. Used for Radiographic visualization of the gastrointestinal tract, Diagnosis of gastrointestinal obstruction and perforation, Evaluation of suspected bowel obstruction in neonates and infants.

At a glance

Generic nameGastrografin®: G
Also known aswater-soluble contrast medium (Gastrografin®: G) meal
SponsorUniversity of Bologna
Drug classIodinated contrast medium
ModalitySmall molecule
Therapeutic areaDiagnostic Imaging
PhaseFDA-approved

Mechanism of action

Gastrografin contains sodium diatrizoate and meglumine diatrizoate, iodinated compounds that absorb X-rays and render the GI tract radiopaque. It is administered orally or rectally and distributes throughout the gastrointestinal lumen, allowing visualization of anatomical structures and pathology on radiographic examination. The iodine content provides the radiopacity necessary for diagnostic imaging.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: